Egrifta (Tesamorelin) Compounding Pharmacy Quality Red Flags to Avoid

What Egrifta (Tesamorelin) Actually Is and Why Sourcing Matters

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). The FDA-approved brand Egrifta SV carries a specific indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. In the key Phase III trials (TRIM pooled N=816), tesamorelin 2 mg subcutaneously daily reduced visceral adipose tissue (VAT) by 18% compared to 3% in the placebo arm at 26 weeks [1].

Because brand-name Egrifta SV carries a list price exceeding $7,000 per month, patients and prescribers have turned to compounding pharmacies. That demand created a market with wildly uneven quality controls.

Why the Supply Chain Is Complicated

Tesamorelin is not a small molecule you can simply synthesize in a licensed pharmacy. It is a 44-amino-acid peptide requiring solid-phase synthesis, correct lyophilization conditions, and validated sterile filling. Each of those steps is a potential failure point.

The FDA's 2023 draft guidance on bulk drug substances clarified that many peptides, including tesamorelin, may not be eligible for 503A or 503B compounding if a commercially available equivalent exists [2]. That guidance has not been finalized as of early 2025, but it has already prompted FDA warning letters to pharmacies compounding bulk peptides without adequate controls.

The Regulatory Stack Every Pharmacy Must Satisfy

A legitimate compounding pharmacy dispensing injectable tesamorelin must comply with all of the following simultaneously:

• USP <797> governs sterile compounding environments, beyond-use dating, and microbial contamination limits [3].
• USP <795> governs non-sterile compounding (relevant for any lyophilized powder kits).
• FDA DSCSA (Drug Supply Chain Security Act) establishes traceability requirements for drug products in interstate commerce.
• State board of pharmacy licensure is required in every state where the pharmacy ships product.
• 503A vs. 503B designation determines whether a pharmacy can compound in anticipation of prescriptions or only on a patient-specific basis.

Failing any single layer of this stack is a red flag. Pharmacies that describe their regulatory situation vaguely, or that claim exemptions without documentation, should be avoided.

Red Flag 1: No Certificate of Analysis or Vague COA Language

The certificate of analysis (COA) is the primary document proving what is actually in the vial. A legitimate COA for injectable compounded tesamorelin includes HPLC purity percentage, mass spectrometry confirmation of molecular identity, endotoxin level, sterility test result, and potency assay.

Pharmacies that provide a COA listing only "purity: meets specifications" without a numerical result are giving you nothing useful. "Meets specifications" is meaningless unless the specification is stated.

What Acceptable HPLC Results Look Like

For injectable peptides, an HPLC purity of 98% or above is the minimum standard consistent with pharmaceutical-grade synthesis. Research published in peer-reviewed literature has documented that peptides synthesized below 95% purity frequently contain deletion sequences, truncated fragments, or oxidation products that may provoke immune reactions or simply fail to bind receptors appropriately [4].

Ask specifically: "Can I see the third-party COA from an ISO 17025-accredited laboratory?" If the pharmacy tests in-house only, or says the COA is proprietary, walk away.

Endotoxin and Sterility Are Non-Negotiable

The USP <85> limulus amebocyte lysate (LAL) test sets the endotoxin limit for parenteral drugs at <5 EU/kg/hr. For a 70 kg patient receiving a typical 2 mg subcutaneous dose, even small endotoxin contamination from the manufacturing environment can cause fever, rigors, and systemic inflammatory responses [3].

Sterility testing per USP <71> must confirm absence of aerobic bacteria, anaerobic bacteria, and fungi. Beyond-use dates on vials must be justified by actual stability data, not estimated by convention.

Red Flag 2: The Pharmacy Cannot Confirm State Licensure

Every state pharmacy board publishes a license lookup tool. Before placing an order, confirm the pharmacy holds an active license both in its home state and, if shipping across state lines, in your state. Many peptide vendors operating as "research chemical" suppliers are not pharmacies at all and hold no license.

The National Association of Boards of Pharmacy (NABP) maintains a ".pharmacy" domain verification program and a "Not Recommended" list of websites with documented violations [5]. Checking that list takes two minutes and may prevent serious harm.

The 503A vs. 503B Distinction and Why It Affects You

A 503A pharmacy compounds only on receipt of a valid patient-specific prescription. It cannot legally sell bulk product or ship to patients without a prescriber relationship. A 503B outsourcing facility may produce larger batches but must register with FDA, submit to FDA inspections, and meet Current Good Manufacturing Practice (CGMP) standards.

If a website sells tesamorelin without requiring a prescription, it is operating outside both 503A and 503B frameworks. Full stop.

Red Flag 3: Price Signals That Testing Was Skipped

Legitimate third-party HPLC and mass-spec analysis from an ISO 17025 lab costs between $200 and $600 per lot. Endotoxin testing adds another $100 to $200. Sterility culture testing adds more. Those costs are built into the price of a properly made product.

Compounded tesamorelin priced at less than $80 to $100 per month for a 2 mg/day dose almost certainly lacks one or more of these testing layers. That is not a guarantee of a quality product at higher prices either, but extreme underpricing is a reliable signal that corners were cut.

The FDA's MedWatch database contains multiple adverse event reports tied to contaminated compounded injectables, including contaminated growth-hormone peptide products that caused injection-site abscesses and systemic infection [6].

The "Research Use Only" Loophole Is Not a Loophole

Websites that label tesamorelin vials "for research use only" or "not for human use" are not selling a legal compounded drug product. They are selling a bulk chemical that has bypassed every pharmacy regulatory layer. There is no required sterility testing, no endotoxin limit, no purity floor, and no pharmacist oversight.

The FDA has sent warning letters specifically targeting companies selling peptides under this label while marketing them to humans through coded language [7]. Purchasing from these sources is both legally risky and medically dangerous.

Red Flag 4: No PCAB Accreditation or Equivalent Third-Party Verification

The Pharmacy Compounding Accreditation Board (PCAB) is the gold-standard accreditation body for compounding pharmacies in the United States. PCAB-accredited pharmacies undergo on-site inspections covering facility design, beyond-use date policies, training records, and quality management systems.

PCAB accreditation is not required by federal law, but its presence signals a pharmacy that has voluntarily submitted to external scrutiny. Its absence is not automatically disqualifying, but combined with any of the other red flags above, it strengthens the case for looking elsewhere.

USP <797> Compliance: What an Inspection Actually Checks

USP <797> (revised effective November 2023) requires that sterile compounding pharmacies maintain [3]:

• ISO Class 5 primary engineering controls (laminar airflow workbenches or isolators)
• ISO Class 7 buffer areas for low- and medium-risk preparations
• Viable and non-viable air sampling on a defined schedule
• Personnel garbing and hand hygiene competency assessments
• Media-fill testing at least annually for each compounder

Ask the pharmacy for its most recent USP <797> compliance certification or inspection outcome. Legitimate facilities will provide it. Facilities that cannot produce documentation of environmental monitoring are not operating to standard.

Red Flag 5: Vague or Missing Prescriber Requirements

Tesamorelin, whether compounded or brand-name, is a prescription drug in the United States. Any source that dispenses it without a valid prescription from a licensed prescriber is breaking federal law under 21 U.S.C. § 353.

Some telehealth platforms now offer tesamorelin prescriptions for off-label uses such as age-related growth hormone deficiency. Off-label prescribing is legal for physicians but does not change the requirement for a genuine prescriber-patient relationship, a documented clinical evaluation, and a valid prescription transmitted to a licensed pharmacy.

Patients who receive tesamorelin vials at home without ever having spoken to a clinician should consider that transaction a major red flag, regardless of what documentation accompanied the shipment.

A Practical Buyer Verification Framework

Use this sequence before placing any order for compounded tesamorelin:

Step 1. Verify the prescription requirement. Confirm the pharmacy requires a prescription from your personal prescriber, or has a licensed physician on staff who will review your records before dispensing.

Step 2. Look up state licensure. Use your state board of pharmacy lookup tool and the NABP site verification tool. Confirm active licensure.

Step 3. Request the full COA. Ask for numerical HPLC purity (accept nothing below 98%), mass-spec identity confirmation, USP <71> sterility result, and USP <85> endotoxin level with the actual EU/mL number.

Step 4. Confirm testing lab independence. The COA should come from a third-party ISO 17025-accredited laboratory, not solely from the compounding pharmacy's in-house team.

Step 5. Confirm 503A or 503B registration. Ask the pharmacy to provide its NPI number and 503B FDA registration number if applicable. Cross-reference on the FDA's registered outsourcing facilities list [8].

Step 6. Check PCAB accreditation. Search the PCAB directory at pcab.pharmacy. Not required, but a strong positive signal.

Step 7. Review pricing against testing costs. Any monthly supply priced below $100 for a 2 mg/day regimen should trigger scrutiny about whether testing was actually performed.

Is Compounded Tesamorelin Legal?

This is the question most patients search first, and the honest answer is: it depends on the specific compounding pathway and changes frequently with FDA guidance.

The 503A Pathway

Under 503A of the Food, Drug, and Cosmetic Act, a licensed pharmacist or physician may compound a drug for an individual patient based on a valid prescription, provided the drug is not essentially a copy of an FDA-approved product [9]. Because Egrifta SV is FDA-approved and commercially available, compounding tesamorelin under 503A is legally questionable unless the prescriber documents that the commercial product is clinically unsuitable for that specific patient (for example, allergy to an excipient).

The 503B Pathway

503B outsourcing facilities may compound drugs that appear on FDA's drug shortage list or in certain other circumstances. Tesamorelin has not appeared on the shortage list as of January 2025, which limits the 503B pathway as well.

What This Means Practically

Consult your prescriber and the compounding pharmacy's pharmacist-in-charge before proceeding. The Endocrine Society's clinical practice guidelines on growth hormone deficiency do not address compounded tesamorelin specifically, but their framework for evaluating treatment adequacy applies: "Biochemical monitoring should use IGF-1 measurements standardized to age- and sex-matched reference ranges" [10]. Any compounded product that does not produce measurable IGF-1 changes at expected doses may be underpotent.

What Research-Grade Tesamorelin Means and Why It Is Not Safe for Injection

The term "research grade" on a peptide website is a marketing construct, not a regulatory category. It signals that the product was not manufactured under pharmacy compounding standards and has not been tested to the levels required for human use.

Research-grade peptide suppliers typically provide HPLC purity certificates, but those certificates cover chemical purity only. They do not confirm sterility, endotoxin levels, absence of residual solvents from synthesis, or correct reconstitution conditions. A 99% pure peptide that is not sterile will cause an abscess or systemic infection when injected.

The CDC has documented outbreaks of Mycobacterium abscessus infections linked to non-sterile injectable cosmetic products, demonstrating how quickly contaminated injectables cause serious harm [11]. The same risk applies to any peptide injected without confirmed sterility testing.

How Egrifta SV Itself Is Quality-Controlled

Understanding the brand standard helps calibrate what you should demand from compounders. Egrifta SV (tesamorelin for injection, 2 mg) is manufactured under FDA-approved New Drug Application (NDA) 022505 [12]. Its manufacturing controls include:

• Validated solid-phase peptide synthesis with defined impurity profiles
• Lyophilization cycle validation ensuring consistent reconstitution
• Release testing for identity, purity, potency, sterility, and endotoxin before each lot ships
• Stability testing supporting labeled shelf life under specified storage conditions

A compounding pharmacy cannot replicate the full NDA infrastructure, but it can and must replicate the release testing. Any pharmacy that cannot document those release tests for each compounded lot is not meeting the minimum standard.

Monitoring Adequacy After You Start

Even with a perfectly made product, you need clinical monitoring to confirm the tesamorelin is working. In the key trials, VAT reduction at 26 weeks was confirmed by CT scan [1]. In most clinical practice settings, IGF-1 levels serve as a surrogate marker of GH axis activity.

If your IGF-1 does not move after 8 to 12 weeks at the prescribed dose, either the product is underpotent, the storage conditions were violated (tesamorelin requires refrigeration and protection from light), or the diagnosis driving the prescription needs re-evaluation. A legitimate compounding pharmacy will provide reconstitution and storage guidance in writing.